- Home
- Publications
- Publication Search
- Publication Details
Title
RET inhibition: implications in cancer therapy
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 17, Issue 4, Pages 403-419
Publisher
Informa Healthcare
Online
2013-03-06
DOI
10.1517/14728222.2013.758715
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RET/PTC1-Driven Neoplastic Transformation and Proinvasive Phenotype of Human Thyrocytes Involve Met Induction and β-Catenin Nuclear Translocation
- (2015) Giuliana Cassinelli et al. NEOPLASIA
- Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers
- (2012) Fei Li et al. CELL RESEARCH
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
- (2012) Jin Soo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
- (2012) P Ballerini et al. LEUKEMIA
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer
- (2012) Cristina Romei et al. THYROID
- ALK Inhibitors, a Pharmaceutical Perspective
- (2012) Elena Ardini et al. Frontiers in Oncology
- The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells
- (2011) Chunyu Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
- (2011) Woo-Jin Jeong et al. CANCER BIOLOGY & THERAPY
- Development of RET Kinase Inhibitors for Targeted Cancer Therapy
- (2011) L. Mologni CURRENT MEDICINAL CHEMISTRY
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism
- (2011) Iván Plaza-Menacho et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas
- (2011) Margarida M. Moura et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer
- (2011) Yariv Houvras JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- RET in breast cancer: functional and therapeutic implications
- (2011) Andrea Morandi et al. TRENDS IN MOLECULAR MEDICINE
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- [18F]Fluorodeoxyglucose Positron Emission Tomography in the Initial Staging of Squamous Cell Carcinoma of the Head and Neck: Promise, Evidence, and Reality
- (2010) Jonas A. de Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC
- (2010) Karin Frank-Raue et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
- (2010) I Plaza-Menacho et al. ONCOGENE
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Multiple endocrine neoplasia type 2RETprotooncogene database: Repository of MEN2-associatedRETsequence variation and reference for genotype/phenotype correlations
- (2009) Rebecca L. Margraf et al. HUMAN MUTATION
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
- (2009) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional RET G691S polymorphism in cutaneous malignant melanoma
- (2009) N Narita et al. ONCOGENE
- Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances
- (2009) Martin Schlumberger et al. THYROID
- High Resolution Array-Comparative Genomic Hybridization Profiling Reveals Deoxyribonucleic Acid Copy Number Alterations Associated with Medullary Thyroid Carcinoma
- (2008) Lei Ye et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, Modeling, and RET Protein Kinase Inhibitory Activity of 3- and 4-Substituted β-Carbolin-1-ones
- (2008) Raffaella Cincinelli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sixty years of follow-up of Hiroshima and Nagasaki survivors: Current progress in molecular epidemiology studies
- (2008) K NAKACHI et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
- (2007) Rossella Elisei et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search